Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 1
2009 4
2010 2
2011 1
2012 1
2013 2
2014 4
2016 4
2017 5
2018 3
2019 5
2020 5
2021 10
2022 1
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Results by year

Filters applied: . Clear all
Page 1
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, Lindsay J, Weisel K, White D, Facon T, San Miguel J, Sunami K, O'Gorman P, Sonneveld P, Robak P, Semochkin S, Schey S, Yu X, Doerr T, Bensmaine A, Biyukov T, Peluso T, Zaki M, Anderson K, Dimopoulos M; OPTIMISMM trial investigators. Richardson PG, et al. Among authors: o gorman p. Lancet Oncol. 2019 Jun;20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4. Epub 2019 May 13. Lancet Oncol. 2019. PMID: 31097405 Clinical Trial.
Maintenance and continuous therapy for multiple myeloma.
Richardson PG, Laubach J, Gandolfi S, Facon T, Weisel K, O'Gorman P. Richardson PG, et al. Among authors: o gorman p. Expert Rev Anticancer Ther. 2018 Aug;18(8):751-764. doi: 10.1080/14737140.2018.1490181. Epub 2018 Jul 3. Expert Rev Anticancer Ther. 2018. PMID: 29932776 Review.
Clinical Proteomics of Biofluids in Haematological Malignancies.
Dunphy K, O'Mahoney K, Dowling P, O'Gorman P, Bazou D. Dunphy K, et al. Among authors: o gorman p. Int J Mol Sci. 2021 Jul 27;22(15):8021. doi: 10.3390/ijms22158021. Int J Mol Sci. 2021. PMID: 34360786 Free PMC article. Review.
Bone disease in multiple myeloma: pathophysiology and management.
Hameed A, Brady JJ, Dowling P, Clynes M, O'Gorman P. Hameed A, et al. Among authors: o gorman p. Cancer Growth Metastasis. 2014 Aug 10;7:33-42. doi: 10.4137/CGM.S16817. eCollection 2014. Cancer Growth Metastasis. 2014. PMID: 25187738 Free PMC article. Review.
Overcoming multiple myeloma drug resistance in the era of cancer 'omics'.
Guang MHZ, McCann A, Bianchi G, Zhang L, Dowling P, Bazou D, O'Gorman P, Anderson KC. Guang MHZ, et al. Among authors: o gorman p. Leuk Lymphoma. 2018 Mar;59(3):542-561. doi: 10.1080/10428194.2017.1337115. Epub 2017 Jun 13. Leuk Lymphoma. 2018. PMID: 28610537 Free PMC article. Review.
COVID-19-induced endotheliitis: emerging evidence and possible therapeutic strategies.
Calabretta E, Moraleda JM, Iacobelli M, Jara R, Vlodavsky I, O'Gorman P, Pagliuca A, Mo C, Baron RM, Aghemo A, Soiffer R, Fareed J, Carlo-Stella C, Richardson P. Calabretta E, et al. Among authors: o gorman p. Br J Haematol. 2021 Apr;193(1):43-51. doi: 10.1111/bjh.17240. Epub 2021 Feb 4. Br J Haematol. 2021. PMID: 33538335 Free PMC article. No abstract available.
47 results